Manufacturing Issue with Xaggitin XL Tablets Reported by Martindale Pharma
A manufacturing defect has been reported for Xaggitin XL Prolonged-release Tablets, affecting tablet counts in multiple batches.
Company
Macarthys Laboratories Ltd
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The reported manufacturing defect in Xaggitin XL Prolonged-release Tablets poses a risk to patient access and market share within the ADHD treatment sector. Continuous monitoring of regulatory updates is essential to mitigate potential disruptions in supply and ensure compliance.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor updates from MHRA regarding the resolution of the manufacturing issue and any potential recalls or patient safety advisories.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.